Drug approvals: Cefixime tablets,Certolizumab, Lisdexamfetamine

Lupin launches Cefixime tablets
Lupin Pharmaceuticals Inc, a wholly owned US subsidiary of Mumbai-based pharma major Lupin Limited, launched Suprax 400 mg tablets (Cefixime USP) in US. With this line extension, Lupin has tightened its grip on the brand franchise of its flagship anti-infective Suprax (Cefixime for oral suspension 100 mg/ 5 ml and 200 mg/ 5ml).
USFDA approves UCB's Certolizumab
UCB announced that USFDA has approved Cimzia (certolizumab pegol), the first and only PEGylated anti-TNF (Tumour Necrosis Factor alpha) antibody indicated for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderate to severe active disease who have an inadequate response to conventional therapy.
USFDA approves Lisdexamfetamine Dimesylate
Shire has received approval from the USFDA for Vyvanse (Lisdexamfetamine Dimesylate), for the treatment of Attention Deficit Hyperactivity Disorder in adults.